Vivaldi Coelho Rogerio sold (to issuer) $1.6M of CRNX
Vivaldi Coelho Rogerio sold (to issuer) 19,225 shares of Crinetics Pharmaceuticals, Inc. (CRNX) at $85.00 ($1.63M total) across 2 trades on 2026-09-01.
How this was made
The 30-second read
Why it matters
The director's complete exit may be interpreted as a negative signal, prompting short interest.
Market read
Insider sale of $1.6M is notable for a micro‑cap biotech and could influence short‑term price action.
What to watch
Potential tax planning or personal financial needs may drive the sale.
Background
Form 4 disclosures provide the first public record of insider transactions.
Ticker impact
Director Vivaldi Coelho Rogerio sold all 19,225 shares for $1.6M via a Form 4 filing.
Short-term downward pressure as the market digests the director's exit.
Director-level insider sales are closely watched; a $1.6M sale is material for a micro‑cap biotech.
Market effects
May raise concerns for other biotech insiders and affect sector sentiment.
Limited to US biotech investors.
Minimal global impact.
Counterpoint
The sale could be a routine liquidity event unrelated to company fundamentals.
Key entities
- CompanyCrinetics Pharmaceuticals, Inc.
Biotech firm developing therapies for rare diseases.
- InsiderVivaldi Coelho Rogerio
Director of Crinetics who sold all holdings.
